Pulmonary Pharmacology · Module 3 of 7

Methylxanthines, Leukotriene Modifiers, and Mast Cell Stabilizers

Theophylline pharmacokinetics and toxicity · Leukotriene pathway · CysLT1 antagonists · 5-LOX inhibition · Aspirin-exacerbated respiratory disease

Theophylline produces bronchodilation via two mechanisms: PDE3/PDE4 inhibition raises cyclic AMP (same final pathway as beta-2 agonists, via a different upstream target); and non-competitive antagonism of adenosine A1/A2B receptors reduces bronchoconstriction and mast cell degranulation. The therapeutic window is 10–20 mcg/mL. Kinetics are Michaelis-Menten (saturable/zero-order at therapeutic concentrations) — small dose increases near enzyme saturation produce disproportionately large concentration increases, making theophylline inherently dangerous. Aminophylline is the IV prodrug (theophylline-ethylenediamine salt, ~80% theophylline by weight).
Theophylline toxicity is organ-system predictable: GI (nausea/vomiting — earliest signs, occur just above therapeutic range); CNS (headache → seizures at severely toxic concentrations; refractory to standard anticonvulsants — high morbidity); cardiac (sinus tachycardia, atrial arrhythmias, ventricular arrhythmias at very high levels). Chronic toxicity causes seizures at lower absolute concentrations than acute overdose. Clearance decreases (toxicity risk): ciprofloxacin/fluoroquinolones, erythromycin, cimetidine, heart failure, liver disease, viral illness, smoking cessation (loss of CYP1A2 induction). Clearance increases (subtherapeutic levels): active smoking, phenytoin, rifampin.
Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are synthesized from arachidonic acid via phospholipase A2 release → 5-lipoxygenase (requiring FLAP cofactor) → LTA4 → glutathione conjugation → LTC4 → sequential peptidase cleavage → LTD4 + LTE4. LTD4 is the most potent bronchoconstrictor: 100–1000× more potent than histamine on a molar basis at CysLT1 receptors. Beyond bronchoconstriction, cysteinyl leukotrienes increase vascular permeability, stimulate mucus secretion, recruit eosinophils, and promote airway remodeling. Two pharmacological targets: 5-LOX inhibition (zileuton — upstream, blocks all leukotriene synthesis) and CysLT1 receptor antagonism (montelukast, zafirlukast — downstream, blocks receptor effect).
Montelukast and zafirlukast are selective competitive CysLT1 antagonists — oral, effective in exercise-induced bronchoconstriction, allergic rhinitis with asthma, and AERD. Montelukast (once-daily) carries a 2020 FDA black box warning for serious neuropsychiatric adverse effects (agitation, depression, suicidal ideation, completed suicides) — particularly concerning in pediatric patients; weigh against benefit in those with psychiatric history. Zileuton inhibits 5-LOX directly (blocks all leukotrienes including LTB4); four-times-daily dosing (or twice-daily XR); significant CYP1A2 inhibitor — raises theophylline levels substantially (reduce theophylline dose and monitor); hepatotoxicity — monitor LFTs.
Aspirin-exacerbated respiratory disease (AERD): clinical triad of asthma + chronic rhinosinusitis with nasal polyposis + hypersensitivity to aspirin/NSAIDs. Mechanism is pharmacological not IgE-mediated: COX-1 inhibition by aspirin/NSAIDs blocks PGE2 production → removes the brake on 5-LOX → cysteinyl leukotriene surge → bronchoconstriction + nasal symptoms within 30–180 minutes. All COX-1 inhibitors trigger reactions (not aspirin-specific). Safe alternatives: acetaminophen <1 g/dose; celecoxib (selective COX-2 inhibitor) at standard doses. Management: avoid NSAIDs; LTRAs (directly address the leukotriene surge); nasal corticosteroids; sinus surgery for polyp burden; aspirin desensitization at specialized centers for patients requiring antiplatelet therapy. Cromolyn sodium and nedocromil (mast cell stabilizers) block chloride channels in mast cell membranes → prevent degranulation; excellent safety profile but require QID dosing and are less effective than low-dose ICS; largely supplanted in adults.

AERD = aspirin-exacerbated respiratory disease · cAMP = cyclic adenosine monophosphate · COX-1 = cyclooxygenase-1 · CysLT1 = cysteinyl leukotriene receptor 1 · FLAP = 5-lipoxygenase-activating protein · LFT = liver function test · LOX = lipoxygenase · LTRA = leukotriene receptor antagonist · LTA4 = leukotriene A4 · LTB4 = leukotriene B4 · LTC4 = leukotriene C4 · LTD4 = leukotriene D4 · LTE4 = leukotriene E4 · PDE = phosphodiesterase · PGE2 = prostaglandin E2 · PKA = protein kinase A · QID = four times daily · TDM = therapeutic drug monitoring · XR = extended-release

Theophylline: Mechanism, Kinetics, and Interactions

Dual Mechanism

PDE Inhibition + Adenosine Antagonism

PDE3/PDE4 inhibition → cyclic AMP ↑ → PKA activation → MLCK inhibition → bronchodilation (same final pathway as beta-2 agonists)
PDE4 inhibition in inflammatory cells → modest anti-inflammatory effect
Adenosine A1/A2B antagonism → reduced bronchoconstriction + mast cell degranulation inhibition
Therapeutic window: 10–20 mcg/mL — TDM mandatory
Aminophylline: IV salt form (~80% theophylline by weight) — dose accordingly

Pharmacokinetics

Michaelis-Menten Kinetics — Non-Linear

Saturable (zero-order) kinetics at therapeutic concentrations — metabolizing enzymes approach saturation
Small dose increases near saturation → disproportionately large plasma level increases
Clearance ↑ (lower levels): cigarette smoking (CYP1A2 induction), phenytoin, rifampin, high-protein diet
Clearance ↓ (toxicity risk): ciprofloxacin, erythromycin, cimetidine, heart failure, liver disease, viral illness, smoking cessation
Smoking cessation in theophylline patient: CYP1A2 induction lost → levels rise → check level promptly

Theophylline Toxicity

Level	GI	CNS	Cardiac
10–20 mcg/mL	Therapeutic — bronchodilation	No toxicity	No toxicity
>20 mcg/mL	Nausea, vomiting, abdominal pain — earliest signs; warning to check level	Headache, irritability, insomnia	Sinus tachycardia, atrial arrhythmias
>30 mcg/mL	Persistent vomiting	Seizures — refractory to standard anticonvulsants; high morbidity; treat with benzodiazepines first	Ventricular arrhythmias — potentially fatal

Chronic vs. Acute Theophylline Toxicity

Chronic toxicity (slow accumulation from impaired clearance) causes seizures at lower absolute concentrations than acute single-dose overdose — chronic exposure allows CNS sensitization to develop. A patient at 25 mcg/mL from a drug interaction may be at greater seizure risk than an acute overdose patient at the same level. Management: activated charcoal (acute ingestion), benzodiazepines for seizures, cardiac monitoring, hemodialysis for refractory life-threatening toxicity.

Leukotriene Biosynthesis Pathway and Drug Targets

Step 1

Arachidonic Acid Release

Phospholipase A2 activated in mast cells, eosinophils, macrophages during allergen challenge
Releases arachidonic acid from membrane phospholipids
Competing fates: COX pathway (PGs, TXA2) vs 5-LOX pathway (leukotrienes)

Step 2 — Drug Target

5-Lipoxygenase + FLAP

FLAP anchors 5-LOX to nuclear membrane and presents arachidonic acid to the enzyme
5-LOX converts arachidonic acid → LTA4
Zileuton inhibits 5-LOX directly → blocks ALL downstream leukotrienes (LTB4 + cysteinyl LTs)

Step 3–4

Cysteinyl Leukotriene Synthesis

LTA4 + glutathione → LTC4 (glutathione transferase)
LTC4 → LTD4 (γ-glutamyl transpeptidase)
LTD4 → LTE4 (dipeptidase)
LTD4 most potent bronchoconstrictor: 100–1000× histamine on molar basis

Step 5 — Drug Target

CysLT1 Receptor

CysLT1 on airway smooth muscle: LTD4 binding → Gq → IP3 → Ca²⁺ → bronchoconstriction
Also: vascular permeability ↑, mucus secretion ↑, eosinophil recruitment, airway remodeling
Montelukast / Zafirlukast block CysLT1 competitively

Leukotriene Modifiers: Clinical Profiles

CysLT1 Antagonist

Montelukast

Once-daily oral; approved for asthma and allergic rhinitis
Effective in exercise-induced bronchoconstriction and AERD
Add-on controller; alternative to low-dose ICS (not preferred first-line)
Black box warning (FDA 2020): serious neuropsychiatric effects — agitation, depression, suicidal ideation, completed suicides; highest concern in children
Weigh psychiatric risk; avoid in patients with pre-existing psychiatric conditions

CysLT1 Antagonist

Zafirlukast

Twice-daily oral; approved for asthma
Effective in exercise-induced bronchoconstriction and AERD
Significant drug interactions: inhibits CYP2C9 (warfarin ↑) and CYP3A4
Post-marketing association with Churg-Strauss syndrome (eosinophilic vasculitis) when corticosteroids tapered — likely unmasking rather than causation
Less commonly used than montelukast due to twice-daily dosing and interactions

5-LOX Inhibitor

Zileuton

Inhibits 5-lipoxygenase directly — blocks ALL leukotrienes (LTB4 + CysLTs), unlike LTRAs
Immediate-release: QID dosing; extended-release: twice-daily
CYP1A2 inhibitor — substantially raises theophylline levels; reduce theophylline dose and monitor levels when combining
Hepatotoxicity — monitor LFTs periodically
Approved as add-on therapy in persistent asthma; useful in AERD

Mast Cell Stabilizers and Aspirin-Exacerbated Respiratory Disease

Mast Cell Stabilizers

Cromolyn / Nedocromil

Block chloride channels in mast cell membranes → prevent degranulation → no histamine, CysLT, or mediator release
Excellent safety profile — no significant systemic adverse effects
Require QID inhaled dosing — poor adherence
Less effective than low-dose ICS — largely supplanted in adults
Residual role: children where parents are concerned about corticosteroid effects; exercise-induced bronchoconstriction prophylaxis when ICS not tolerated

AERD — Mechanism

COX-1 Inhibition → Leukotriene Surge

COX-1 inhibition by aspirin/NSAIDs blocks PGE2 — normally restrains 5-LOX and mast cell activation
PGE2 loss → 5-LOX unopposed → cysteinyl leukotriene surge → bronchoconstriction + nasal symptoms within 30–180 min
Pharmacological (not IgE-mediated) → all COX-1 inhibitors trigger reactions, not aspirin alone
Safe alternatives: acetaminophen <1 g/dose; celecoxib (selective COX-2) at standard doses

AERD Management and Aspirin Desensitization

Avoid all COX-1 inhibitors. Leukotriene receptor antagonists are particularly effective in AERD because leukotriene excess is the direct pharmacological mechanism of the reaction — they directly counter the surge. Nasal corticosteroids for rhinosinusitis. Endoscopic sinus surgery for polyp burden refractory to medical therapy.

Aspirin desensitization — performed at specialized centers under controlled conditions — allows gradual tolerance to aspirin in patients who require antiplatelet therapy for cardiovascular indications. Once desensitized, the patient must continue daily aspirin to maintain tolerance; stopping and restarting resets sensitivity.

Zileuton + Theophylline — Dangerous Combination

Zileuton is a significant inhibitor of CYP1A2 — the primary enzyme responsible for theophylline metabolism. Co-administration substantially raises theophylline plasma concentrations, potentially pushing levels above the therapeutic window into the toxic range. If the combination is clinically necessary, the theophylline dose must be reduced and plasma levels monitored closely. Theophylline toxicity in this context is preventable with awareness of the interaction.

Suggested References

Author / Source	Title	Publication
Katzung BG (ed)	Basic and Clinical Pharmacology, 15th ed.	McGraw-Hill, 2021
Brunton LL, Knollmann BC (eds)	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed.	McGraw-Hill, 2023
Barnes PJ	Theophylline	Am J Respir Crit Care Med. 2013;188(8):901–906
Hendeles L, Weinberger M	Theophylline: a state of the art review	Pharmacotherapy. 1983;3(1):2–44
Shannon M	Life-threatening events after theophylline overdose: a 10-year prospective analysis	Arch Intern Med. 1999;159(9):989–994
Zevin S, Benowitz NL	Drug interactions with tobacco smoking: an update	Clin Pharmacokinet. 1999;36(6):425–438
Samuelsson B	Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation	Science. 1983;220(4597):568–575
Drazen JM, Israel E, O'Byrne PM	Treatment of asthma with drugs modifying the leukotriene pathway	N Engl J Med. 1999;340(3):197–206
Clarridge K, Chin S, Eworuke E, Seymour S	A boxed warning for montelukast: the FDA perspective	J Allergy Clin Immunol Pract. 2021;9(7):2638–2641
Wechsler ME, Garpestad E, Flier SR, et al	Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast	JAMA. 1998;279(6):455–457
Stevenson DD, Szczeklik A	Clinical and pathologic perspectives on aspirin sensitivity and asthma	J Allergy Clin Immunol. 2006;118(4):773–786
Israel E, Reddel HK	Severe and difficult-to-treat asthma in adults	N Engl J Med. 2017;377(10):965–976